AngioDynamics (ANGO) Misses Q3 EPS by 3c, Revenues Miss; Reiterates FY19 EPS/Revenue Mid-Point Guidance Below Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
KeyBanc Upgrades AngioDynamics (ANGO) to Overweight
April 1, 2019 2:06 PM EDTKeyBanc analyst Matthew Mishan upgraded AngioDynamics (NASDAQ: ANGO) from Sector Weight to Overweight with a price target of $33.00.
For an analyst ratings summary and ratings history on AngioDynamics click here. For more ratings news on AngioDynamics click here.
Shares of AngioDynamics closed at $22.86 yesterday.
... MoreAngioDynamics (ANGO) Granted FDA Approval to Begin NanoKnife DIRECT Clinical Study for Treatment of Stage III Pancreatic Cancer
April 1, 2019 6:09 AM EDTAngioDynamics, Inc. (NASDAQ: ANGO) today announced that the United States Food and Drug Administration (FDA) approved the Companys investigational device exemption (IDE) application for its NanoKnife® Irreversible Electroporation Direct IRE Cancer Treatment clinical study (DIRECT).
The DIRECT Study supports a proposed expanded indication for the NanoKnife System in the treatment of Stage III pancreatic cancer. In January 2018, the FDA granted the Companys NanoKnife System a Breakthrough Device Designation under the 21st... More
